The variable nature of the fusion partners and chromosomal alterations within the TFE3-fusion RCC tumors led us to perform a broad spectrum drug screen in 3 TFE3-fusion RCC cell lines (UOK109, UOK124, UOK145) with 3 different fusion partners to identify agents that would be effective across all fusions. Here, TFE3 is linked to renal cell carcinoma.